Jan Clerinx, Ula Maniewski, Steven Van Den Broucke, Patrick Soentjens, Liselotte Cnops, Marjan Van Esbroeck, Emmanuel Bottieau
{"title":"旅行者中的急性血吸虫病:短期治疗的结果。","authors":"Jan Clerinx, Ula Maniewski, Steven Van Den Broucke, Patrick Soentjens, Liselotte Cnops, Marjan Van Esbroeck, Emmanuel Bottieau","doi":"10.1093/jtm/taaf065","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Therapy of acute schistosomiasis in travellers currently relies on poorly consistent combinations of corticosteroids and praziquantel. In a cluster of travellers recently infected with Schistosoma mattheei × Schistosoma haematobium hybrids during a trip to South Africa in 2017, we evaluated the safety and efficacy of short methylprednisolone cycles to suppress early symptoms and of a single-day praziquantel/methylprednisolone administration at well-defined time lapses.</p><p><strong>Methods: </strong>Symptomatic patients seen during the early phase, 4 to 5 weeks (week 4-5) after infection, were given oral methylprednisolone 0.5 mg/kg once daily in one or more cycles of three consecutive days until symptoms abated. Patients were seen again at week 7-8 to be given praziquantel 40 mg/kg in two divided doses 2 hours apart, followed by a single dose of oral methylprednisolone 0.5 mg/kg 2 hours later to prevent symptom exacerbation. All patients were reevaluated for symptoms and infection at week 12-14, using serum circulating anodic antigen (CAA) as a marker of active infection.</p><p><strong>Results: </strong>A total of 34 infected individuals were longitudinally followed up. Of these, 21 patients with symptoms at presentation (week 4-5) were given methylprednisolone. Symptoms abated during the first three-day cycle in 15/21 (71%), during the second cycle in another 4/21 (19%), and during the third cycle in the remaining 2/21 (10%). All 34 participants were treated with the praziquantel/steroid combination at week 7-8; 9 (26%) had mild symptoms of short duration. Only 4 (12%) developed fever and needed 1 or 2 additional days of steroids. At week 12-14, serum CAA remained detectable in only one of the 34 participants.</p><p><strong>Conclusion: </strong>In most patients, a single three-day course of methylprednisolone was sufficient to suppress symptoms of acute schistosomiasis. Only few patients experienced short lived symptom exacerbation after taking a single-day praziquantel and methylprednisolone combination at 7-8 weeks following exposure. Infection was cleared in almost all cases 4-6 weeks later.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491658/pdf/","citationCount":"0","resultStr":"{\"title\":\"Acute schistosomiasis in travellers: outcomes of a short-course therapy.\",\"authors\":\"Jan Clerinx, Ula Maniewski, Steven Van Den Broucke, Patrick Soentjens, Liselotte Cnops, Marjan Van Esbroeck, Emmanuel Bottieau\",\"doi\":\"10.1093/jtm/taaf065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Therapy of acute schistosomiasis in travellers currently relies on poorly consistent combinations of corticosteroids and praziquantel. In a cluster of travellers recently infected with Schistosoma mattheei × Schistosoma haematobium hybrids during a trip to South Africa in 2017, we evaluated the safety and efficacy of short methylprednisolone cycles to suppress early symptoms and of a single-day praziquantel/methylprednisolone administration at well-defined time lapses.</p><p><strong>Methods: </strong>Symptomatic patients seen during the early phase, 4 to 5 weeks (week 4-5) after infection, were given oral methylprednisolone 0.5 mg/kg once daily in one or more cycles of three consecutive days until symptoms abated. Patients were seen again at week 7-8 to be given praziquantel 40 mg/kg in two divided doses 2 hours apart, followed by a single dose of oral methylprednisolone 0.5 mg/kg 2 hours later to prevent symptom exacerbation. All patients were reevaluated for symptoms and infection at week 12-14, using serum circulating anodic antigen (CAA) as a marker of active infection.</p><p><strong>Results: </strong>A total of 34 infected individuals were longitudinally followed up. Of these, 21 patients with symptoms at presentation (week 4-5) were given methylprednisolone. Symptoms abated during the first three-day cycle in 15/21 (71%), during the second cycle in another 4/21 (19%), and during the third cycle in the remaining 2/21 (10%). All 34 participants were treated with the praziquantel/steroid combination at week 7-8; 9 (26%) had mild symptoms of short duration. Only 4 (12%) developed fever and needed 1 or 2 additional days of steroids. At week 12-14, serum CAA remained detectable in only one of the 34 participants.</p><p><strong>Conclusion: </strong>In most patients, a single three-day course of methylprednisolone was sufficient to suppress symptoms of acute schistosomiasis. Only few patients experienced short lived symptom exacerbation after taking a single-day praziquantel and methylprednisolone combination at 7-8 weeks following exposure. Infection was cleared in almost all cases 4-6 weeks later.</p>\",\"PeriodicalId\":17407,\"journal\":{\"name\":\"Journal of travel medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491658/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of travel medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jtm/taaf065\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of travel medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jtm/taaf065","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景:目前旅行者急性血吸虫病的治疗依赖于皮质类固醇和吡喹酮的不一致的组合。在2017年南非旅行期间感染了马修血吸虫X S. haematobium杂交体的一群旅行者中,我们评估了甲基强的松龙短周期抑制早期症状的安全性和有效性,以及在明确的时间间隔内给予吡喹酮/甲基强的松龙一天。方法:感染后早期4 ~ 5周(4 ~ 5周)出现症状的患者口服甲泼尼龙0.5mg/kg,每日1次,连续3天,1个或多个周期,直至症状减轻。在w7-8时再次观察患者,给予吡喹酮40mg/kg,分两剂,间隔2小时,2小时后口服甲强的松龙0.5mg/kg单剂,以防止症状加重。所有患者在w12-14时重新评估症状和感染,使用血清循环阳极抗原(CAA)作为活动性感染的标志物。结果:共对34例感染者进行了纵向随访。其中,21例出现症状的患者(w4-5)给予甲基强的松龙治疗。15/21的第一个三天周期症状减轻(71%),另一个4/21的第二个周期症状减轻(19%),其余2/21的第三个周期症状减轻(10%)。所有34名参与者在w7-8时接受吡喹酮/类固醇联合治疗;9例(26%)症状轻微,持续时间短。只有4例(12%)出现发烧,并需要额外1或2天的类固醇治疗。在w12-14时,34名参与者中只有一人的血清中仍可检测到CAA。结论:在大多数患者中,甲强的松龙三天疗程足以抑制急性血吸虫病的症状。只有少数患者在暴露后7-8周服用吡喹酮和甲基强的松龙联合用药后出现短期症状恶化。4 ~ 6周后,几乎所有病例感染均被清除。
Acute schistosomiasis in travellers: outcomes of a short-course therapy.
Background: Therapy of acute schistosomiasis in travellers currently relies on poorly consistent combinations of corticosteroids and praziquantel. In a cluster of travellers recently infected with Schistosoma mattheei × Schistosoma haematobium hybrids during a trip to South Africa in 2017, we evaluated the safety and efficacy of short methylprednisolone cycles to suppress early symptoms and of a single-day praziquantel/methylprednisolone administration at well-defined time lapses.
Methods: Symptomatic patients seen during the early phase, 4 to 5 weeks (week 4-5) after infection, were given oral methylprednisolone 0.5 mg/kg once daily in one or more cycles of three consecutive days until symptoms abated. Patients were seen again at week 7-8 to be given praziquantel 40 mg/kg in two divided doses 2 hours apart, followed by a single dose of oral methylprednisolone 0.5 mg/kg 2 hours later to prevent symptom exacerbation. All patients were reevaluated for symptoms and infection at week 12-14, using serum circulating anodic antigen (CAA) as a marker of active infection.
Results: A total of 34 infected individuals were longitudinally followed up. Of these, 21 patients with symptoms at presentation (week 4-5) were given methylprednisolone. Symptoms abated during the first three-day cycle in 15/21 (71%), during the second cycle in another 4/21 (19%), and during the third cycle in the remaining 2/21 (10%). All 34 participants were treated with the praziquantel/steroid combination at week 7-8; 9 (26%) had mild symptoms of short duration. Only 4 (12%) developed fever and needed 1 or 2 additional days of steroids. At week 12-14, serum CAA remained detectable in only one of the 34 participants.
Conclusion: In most patients, a single three-day course of methylprednisolone was sufficient to suppress symptoms of acute schistosomiasis. Only few patients experienced short lived symptom exacerbation after taking a single-day praziquantel and methylprednisolone combination at 7-8 weeks following exposure. Infection was cleared in almost all cases 4-6 weeks later.
期刊介绍:
The Journal of Travel Medicine is a publication that focuses on travel medicine and its intersection with other disciplines. It publishes cutting-edge research, consensus papers, policy papers, and expert reviews. The journal is affiliated with the Asia Pacific Travel Health Society.
The journal's main areas of interest include the prevention and management of travel-associated infections, non-communicable diseases, vaccines, malaria prevention and treatment, multi-drug resistant pathogens, and surveillance on all individuals crossing international borders.
The Journal of Travel Medicine is indexed in multiple major indexing services, including Adis International Ltd., CABI, EBSCOhost, Elsevier BV, Gale, Journal Watch Infectious Diseases (Online), MetaPress, National Library of Medicine, OCLC, Ovid, ProQuest, Thomson Reuters, and the U.S. National Library of Medicine.